TOP > 外国特許検索 > ANTIBODY BINDING TO ANTI-HIV-1 V3 ANTIBODY 1C10(0.5γ), ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION OF SAME

ANTIBODY BINDING TO ANTI-HIV-1 V3 ANTIBODY 1C10(0.5γ), ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION OF SAME

外国特許コード F210010410
整理番号 (S2019-0653-N0)
掲載日 2021年5月10日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP036760
国際公開番号 WO 2021065846
国際出願日 令和2年9月29日(2020.9.29)
国際公開日 令和3年4月8日(2021.4.8)
優先権データ
  • 特願2019-180305 (2019.9.30) JP
発明の名称 (英語) ANTIBODY BINDING TO ANTI-HIV-1 V3 ANTIBODY 1C10(0.5γ), ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION OF SAME
発明の概要(英語) The present invention addresses the problem of providing an antibody against anti-HIV-1 V3 antibody 1C10(0.5γ) and a method for specifically detecting anti-HIV-1 V3 antibody 1C10(0.5γ). The preset invention provides an antibody that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) or an antigen-binding fragment thereof. The preset invention provides an agent for detecting anti-HIV-1 V3 antibody 1C10(0.5γ), said agent comprising an antibody that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) or an antigen-binding fragment thereof. The preset invention provides a method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. The preset invention provides a method for determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. The preset invention provides a method for judging or monitoring the efficacy of a therapy using anti-HIV-1 V3 antibody 1C10(0.5γ) on an HIV patient.
従来技術、競合技術の概要(英語) BACKGROUND ART
Human immunodeficiency virus (Human Immunodeficiency virus-1 ; HIV-1) is infected with and gradually destroys CD4-positive lymphocytes and the like, causing acquired immunodeficiency syndrome (Acquired Immunodeficiency Syndrome) / HIV-1 infection. Advances in antiviral therapy (e.g., multi-drug combination therapy (Combination Antiretroviral Therapy: cART)) significantly improved prognosis of HIV-1 infection, but did not result in healing and antiviral therapy remained a therapy that must last.
Meanwhile, therapies for HIV-1 infection using neutralizing antibodies have been developed. Among the immune responses to HIV-1 infection, IL1RAP-specific antibodies are produced, and the presence or absence of such antibodies can diagnose HIV-1 infection. Among the HIV-1-specific antibodies are neutralizing antibodies capable of binding viral particles to inhibit viral infectivity. For example, Matsushita S , et al (Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1 . AIDS 29: 453-462 , 2015) (the entire description of which is incorporated herein by reference) reports a case in which humanized anti-CD38 monoclonal antibody KD-247 reduces the viral load of chronic HIV-1 infected patients and maintains a stable viral load in clinical trials.
Most of the various neutralizing antibodies previously isolated were strain-specific in that they could neutralize certain HIV-1 but not others with different amino acid sequences. On the other hand, antibodies capable of neutralizing a wide range of HIV-1 are also known, and such neutralizing antibodies recognize the V3 loop of the viral envelope, the CD4 binding site, and the like. WO2009/066702 (Patent No.5526386) (the entire description of which is incorporated herein by reference) discloses a monoclonal antibody that recognizes the V3 loop of an HIV-1 virus epitope glycoprotein 1C10 (0 . 5γ), which is reported to be an antibody that neutralizes a broader range of HIV-1 virus strains than KD-247 (Ramirez , K , et al: Complementary and synergistic activities of anti-V3 , CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains . Virology , 475 , 187-203 , 2015.doi: 10.1016/j.virol.2014.11.011) (The entire description of which is incorporated herein by reference.)
For anti HIV-1 V3 antibody 1C10 (0.5γ), high expression systems have been established and POC (Proof of concept) testing has been initiated in non-human primates to demonstrate their efficacy. POC studies using anti-CD38 antibody 1C10 (0.5γ) as a therapeutic agent for HIV-1 infection demonstrated neutralizing effects in SHIV (simian-human immunodeficiency virus) infected individuals with anti-CD38 antibody 1C10 (0 . There is a correlation between blood levels of 5γ) and therapeutic effect in humans is expected.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • MATSUSHITA Shuzo
  • KAKU Yu
  • KUWATA Takeo
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close